The efficacy of camrelizumab in the treatment of advanced hepatocellular carcinoma complicated with hepatitis B virus infection
10.3760/cma.j.cn115455-20220317-00192
- VernacularTitle:卡瑞利珠单抗治疗晚期肝癌合并乙型肝炎病毒感染的疗效观察
- Author:
Song WANG
1
;
Xinglai GUO
;
Xiangxiang LI
;
Ying ZHANG
Author Information
1. 阜阳市肿瘤医院肿瘤内科，阜阳 236000
- Keywords:
Liver neoplasms;
Hepatitis B virus;
Camrellizumab;
Entecavir
- From:
Chinese Journal of Postgraduates of Medicine
2023;46(11):1015-1020
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of camrelizumab in the treatment of advanced hepatocellular carcinoma complicated with hepatitis B virus infection.Methods:One hundred cases of patients with advanced primary hepatocellular carcinoma complicated with hepatitis B virus infection admitted to the Fuyang Cancer Hospital from July 2020 to July 2021 were selected and divided into the observation group (48 cases) and the control group (52 cases) by the random number table method. The control group was treated with transhepatic arterial chemoembolization (TACE) and entecavir, and the observation group was treated with camrelizumab on the basis of the control group. After 3 months of treatment, the efficacy was evaluated, serum Alpha-fetoprotein (AFP) was determined, and the incidence of adverse reactions was counted. Progression-free survival (PFS) and overall survival (OS) were compared in follow-up visits.Results:After 3 months of treatment, the objective remission rates of the observation group and the control group were 47.92% (23/48) and 23.08% (12/52), respectively, and the disease control rates were 85.42% (41/48) and 65.38% (34/52), respectively, with statistically significant differences ( P<0.05); the AFP level in the observation group was significantly lower than that in the control group: (55.41 ± 10.22) μg/L vs. (78.52 ± 9.63) μg/L, with statistically significant differences ( P<0.05); the incidence of reactive skin capillary hyperplasia in the observation group was significantly higher than that in the control group: 83.33% (40/48) vs. 0, with statistically significant differences ( P<0.05); the median PFS and OS in the observation group were significantly longer than those in the control group: 8.00 (6.27, 9.73) months vs. 5.90 (4.70, 7.10) months and 15.50 (13.47, 17.00) months vs. 12.80 (10.21, 15.39) months, with statistically significant differences ( P<0.05). Conclusions:Camrelizumab combined with entecavir and TACE is effective in the treatment of patients with advanced hepatocellular carcinoma complicated with hepatitis B virus infection. Compared with the short-term efficacy and long-term survival of entecavir alone combined with TACE, camrelizumab combined with TACE is more advantageous, and the degree of adverse reactions is less. Therefore, this regimen may have better benefits when considering the efficacy and tolerability.
